Skip to main content
Diabetes, Metabolic Syndrome and Obesity logoLink to Diabetes, Metabolic Syndrome and Obesity
. 2022 Jan 10;15:79–91. doi: 10.2147/DMSO.S341935

Kidney Function and Risk of Physical and Cognitive Impairment in Older Persons with Type 2 Diabetes at an Outpatient Clinic with Geriatric Assessment Implementation

Cheng-Fu Lin 1,2, Hsiu-Chen Liu 3, Shih-Yi Lin 1,4,5,
PMCID: PMC8759987  PMID: 35046679

Abstract

Purpose

Diabetes is associated with an increased risk of cognitive and physical functional decline that may impede disease self-management. By incorporating cognitive and physical function assessment, this study aimed to evaluate prevalence and factors associated with cognitive and physical dysfunction in older diabetic people.

Methods

The cross-sectional study was performed from August 1, 2017 to November 30, 2018. The patients aged 65 years or older with type 2 diabetes mellitus were enrolled and the disease was routinely evaluated by blood hemoglobin A1c (A1C), blood pressure, lipids, and kidney function measured by estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine rate (UACR). Besides, cognitive dysfunction through Mini-mental State Examination (MMSE), and functional disabilities by Activities of Daily Living (ADL) questionnaire were assessed simultaneously.

Results

Among 863 patients (48.3% men) with a median age of 72.0 years (interquartile range or IQR: 67.0–78.0 years), 159 (18.5%) had cognitive impairment assessed by MMSE, while 40 (4.6%) experienced at least one problem in ADL. With different A1C stratifications, it was shown that both MMSE and ADL scores were associated with glycemic control. Patients with impaired MMSE and ADL scores were older, had lower eGFR, lower blood pressure, and higher UACR levels. After adjustment of possible confounders, it was shown that age and eGFR predicted MMSE and ADL score impairment.

Conclusion

By incorporating physical and cognitive function screening program into routine care at a diabetes outpatient clinic, our study found that both cognitive and physical function impairment were common in older diabetic patients, and their relevant factors, including older age, and lower eGFR. It was recommended that in older individuals with diabetes, particularly those with risk factors, an additional assessment of cognitive and physical functions can be integrated into routine clinical process to provide more comprehensive management plans.

Keywords: diabetes, aged, outpatient, functional decline, cognitive impairment

Introduction

Diabetes is a risk factor for cognitive impairment and dementia. Individuals diagnosed with diabetes are 1.5 times more likely to experience cognitive decline and early stage of dementia than individuals without diabetes.1 The abnormalities in cognitive functions due to dementia may cause significant difficulty in the management of the disease, and may also impede self-management behavior, particularly given the high complexity of diabetes treatment regimens (eg, blood glucose testing, meal planning and medication adhesion).2 Importantly, patients experiencing such cognitive disorders are unlikely to self-report either their cognitive problems or difficulty in managing their diabetes, requiring early identification of cognitive disorder in diabetic patients by health-care providers be imperative.

In addition to increasing the risk of cognitive dysfunction, epidemiological studies have indicated that individuals with diabetes generally have a 2 to 3 times greater risk of functional disability in terms of Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADL), and mobility-related tasks when compared with individuals without diabetes.3 The physical functional decline seen among diabetic patients is associated with disease control and its complications.3 As a consequence, patients were at a high risk for more advanced dependence, hospitalizations, and a greater need for disability-related health resources.

Previous studies performed in Taiwan have reported an increased risk of physical disability, cognitive impairment, and depression symptoms in diabetic patients.4–6 However, the association between diabetic complications, metabolic controls and prescribed medications with physical and cognitive disability have been less detailed. In Taiwan’s diabetes pay-for-performance program, vascular complications, blood glucose, lipid, and blood pressure control examinations as well as diabetes education are performed regularly at diabetes outpatient clinics.7 It has been hypothesized that through additional cognition and physical function assessment their association with glycemic control and other diabetes-relevant factors in older adults with diabetes can be elucidated, and benefit for management and support in these population. In this study, we aimed to incorporate assessment of cognitive and physical functions at a diabetes outpatient clinic, and examine the prevalence of physical, cognitive impairment and explore potential risk factors in older adults with diabetes.

Materials and Methods

Study Design

Since August 1, 2017, our diabetes outpatient clinics have incorporated the Mini-mental State Examination (MMSE), 5-item Geriatric Depression Scale (GDS-5), ADL and IADL scale assessments into the diabetes pay-for-performance program in Taiwan. At the annual visit of diabetes pay-for-performance program, evaluation of diabetic complications, blood glucose, lipid, blood pressure control, and other laboratory examinations were all required as well as diabetes education.7 When diabetes education was performed, cognitive and physical functions were also assessed by well-trained nurse educators. In the study, the baseline survey data collected between August 1, 2017 and November 30, 2018 were analyzed anonymously in cross-sectional manner. The study was approved by the Institutional Review Board (IRB) of the hospital (No: CE18117A), with the IRB waiving the requirement of verbal or written consent from the enrolled subjects and the patient data accessed was treated with confidentiality.

Participants

Subjects who were aged 65 years or older with a diagnosis of type 2 diabetes mellitus, and had participated in the diabetes pay-for-performance program at our diabetes outpatient clinic were enrolled in the study. Participants with an established diagnosis of dementia, those needing an interpreter, or those with severe visual impairment (unable to complete the tests) were excluded. Based upon previous reports,1–3 we estimated that there would be a prevalence of 10% of the subjects experiencing cognitive impairment and 40% having physical function impairment in older persons with diabetes. We used 5% as a margin error, and 95% as the confidence interval in order to calculate the sample size. Accordingly, the minimal sample size should be no less than 369. Ultimately, a total of 863 patients were enrolled between August 1, 2017 and November 30, 2018.

Demographics and Clinical Information of Participants

Medical records of all enrolled participants were reviewed, including age, gender, education level, comorbidities, medications, disease duration, Body Mass Index (BMI), blood pressure, and laboratory examinations, including hemoglobin A1c (A1C) measured using a boronate affinity high-performance liquid chromatography method (Trinity Biotech Premier Hb9210, Ireland), fasting plasma glucose (FPG), triglyceride (TG), low-density lipoproteins (LDL) cholesterol, creatinine (Cr), and urine albumin-creatinine ratio (UACR) with a chemistry analyzer (Hitachi Labospect 008, Tokyo, Japan), and estimated glomerular filtration rate (eGFR) determined by the formula of the Modification of Diet in Renal Disease (MDRD) equation for Taiwanese adults.8

Measurement of Cognitive Function

The MMSE for cognitive screening included specific questions related to attention, orientation, memory, calculation, and language. The score range was from 0 to 30 and in accordance with the patient’s educational level, with the stratification of the cut-off points for possible dementia determined as follows: MMSE score 24 if the patient was literate; MMSE score 13 if the patient was illiterate.9 The GDS-5 was used for depressive symptoms where a score of 2 or higher indicated depressive symptoms.10

Measurement of Physical Function

Results from both the Barthel index for ADL and the Lawton IADL scale were evaluated for activities of daily living, with most of the patients completing the questionnaires on their own. The Barthel index of ADL assesses the basic ability to meet one’s own physical needs, including feeding, ambulating, dressing, personal hygiene, continence, and toileting, and is scaled between 0 and 100 with low scores representing the severity of dependence.8 The ADL cutoff scores were defined as ADL = 100 for an independent and ADL <100 for one who is non-independent.8 The Lawton IADL scale assesses more complex skills, including the ability to properly use transportation, shopping, managing of finances, taking medications, meal preparation, housecleaning, and communication with others, and is scaled between 0 and 8, with low scores indicating that the patient requires outside assistance.8

Determination of Potential Risk Factors

Potential risk factors were examined included clinical information, demographics, and geriatric assessment of cognitive and physical functions. All assessments were performed by a well-trained nurse educator and the variables listed were potential confounders, therefore, warranted inclusion in the statistical models.

Statistical Analysis

Continuous variables were expressed as median and interquartile range (IQR, 25%−75%). Categorical data were expressed as number and percentage. Comparisons between quantitative groups were performed using the Mann–Whitney U-test, while the chi-square test/Fisher’s exact test were used for categorical ones. Univariate and multivariable logistic regression models were used to examine the associations between binary outcomes (normal and impaired MMSE, ADL, and IADL scores) and covariates (age, gender, disease duration, comorbidities, diabetic complications, medications, and physical and laboratory examination data). Due to the exploratory nature of the analysis for the outcomes in this study, no correction for multiple comparisons was performed.11,12 Statistical analyses were performed using SPSS version 22.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was set at p < 0.05.

Results

Baseline Characteristics of the Participants

The characteristics of the study population and the treatment modalities are shown in Table 1. The median age was 72.0 years (interquartile range or IQR: 67.0–78.0 years) with a female-to-male ratio of 52:48. The educational levels were: 13.4% illiterate, and 86.6% literate. Insulin (not including oral insulin medication) was used by 4.8% of the patients. The most common comorbidities were hyperlipidemia, hypertension, and nephropathy. Polypharmacy (currently using >4 drugs) was occurring in 512 patients. In total, 159 (18.5%) of all patients had an MMSE score below the cutoff value, while 8.3% of the patients had a GDS score greater or equal to 2. Forty (4.6%) patients had at least one physical functional problem assessed by ADL, while 470 (54.5%) patients had at least one abnormal IADL component. The median A1C, representing glycemic control, was 7.1 (IQR: 6.5–7.9).

Table 1.

Baseline Characteristics of the Participants

Demographic Characteristics
Age (years) 72.0 (67.0–78.0)
Sex, n(%)
 Female 446 (51.7%)
 Male 417 (48.3%)
Educational level, n(%)
 Illiterate 115 (13.4%)
 Literate 745 (86.6%)
Geriatric characteristics
Polypharmacy, n (%)
 No 351 (40.6%)
 Yes 512 (59.3%)
Mini-mental state examination 27.0 (24.0–29.0)
5-item Geriatric Depression Scale 0 (0–1.0)
 Barthel index 100.0 (100.0–100.0)
 Lawton scale 7.0 (6.0–8.0)
Diabetes characteristics
Duration (years) 13.0 (7.0–19.0)
Cardiovascular disease 572 (66.3%)
Neuropathy 82 (9.5%)
Retinopathy 27 (3.1%)
Body mass index (kg/m2) 24.8 (22.5–27.3)
Systolic blood pressure (mmHg) 130.0 (121.0–140.0)
Diastolic blood pressure (mmHg) 72.0 (63.0–79.0)
Blood hemoglobin A1c (%) 7.1 (6.5–7.9)
Fasting plasma glucose (mg/dL) 130.0 (112.0–153.0)
Triglycerides (mg/dL) 104.0 (73.0–150.0)
Low-density lipoprotein cholesterols (mg/dL) 82.0 (68.0–99.0)
Blood creatinine (mg/dL) 1.0 (0.8–1.3)
Estimated glomerular filtration rate (mL/min/1.73m2) 70.4 (50.9–87.0)
Urine albumin-creatinine ratio (mg/g) 25.2 (9.6–99.7)
Treatment
 Lifestyle modification 87 (10.1%)
 Oral medications only 593 (68.7%)
 Insulin only 41 (4.8%)
 Oral medications + insulin 142 (16.5%)

Comparison According to A1C

According to different A1C stratifications, good glycemic control is defined as an A1C level <7.0%, intermediate glycemic control an A1C level of 7.0–9.0%, and poor glycemic control an A1C level ≥9.0%. It was shown that diabetes duration, educational level, polypharmacy, BMI, FPG, TG, UACR, MMSE, and ADL scores were all associated with glycemic control status (Table 2). However, impaired ADL, IADL, and MMSE scores were not associated with other diabetic complications, including cardiovascular disease, neuropathy and retinopathy (Tables 25).

Table 2.

Characteristics of Participants According to A1C

Characteristics A1C p value
<7 (n = 371) 7 ≤ Value <9 (n = 405) ≥9 (n = 87)
Demographic characteristics
Age 73.0 (68.0–78.0) 71.0 (67.0–77.0) 72.0 (69.0–79.0) 0.068
Gender, n(%) 0.107
 Female 177 (47.7%) 224 (55.3%) 45 (51.7%)
 Male 194 (52.3%) 181 (44.7%) 42 (48.3%)
Educational level, n(%) 0.540
 Illiterate 54 (14.6%) 52 (12.8%) 9 (10.5%)
 Literate 315 (85.4%) 353 (87.2%) 77 (89.5%)
Geriatric characteristics
Polypharmacy, n(%) <0.001
 No 188 (50.7%) 142 (35.1%) 21 (24.1%)
 Yes 183 (49.3%) 263 (64.9%) 66 (75.9%)
Mini-mental state examination 27.0 (24.0–29.0) 27.0 (24.0–29.0) 26.0 (22.0–28.0) 0.027
5-item Geriatric Depression Scale 0 (0–1.0) 0 (0–1.0) 0 (0–1.0) 0.679
 Barthel index 100.0 (100.0–100.0) 100.0 (100.0–100.0) 100.0 (100.0–100.0) 0.014
 Lawton scale 7.0 (6.0–8.0) 7.0 (6.0–8.0) 7.0 (6.0–8.0) 0.161
Diabetes characteristics
Duration (years) 11.0 (6.0–16.0) 15.0 (9.0–21.0) 16.0 (11.0–22.0) <0.001
Cardiovascular disease, n(%) 0.214
 No 129 (34.8%) 140 (34.6%) 22 (25.3%)
 Yes 242 (65.2%) 265 (65.4%) 65 (74.7%)
Neuropathy, n(%) 0.028
 No 346 (93.3%) 361 (89.1%) 74 (85.1%)
 Yes 25 (6.7%) 44 (10.9%) 13 (14.9%)
Retinopathy, n(%) 0.426
 No 362 (97.6%) 389 (96.1%) 85 (97.7%)
 Yes 9 (2.4%) 16 (3.9%) 2 (2.3%)
Body mass index (kg/m2) 24.7 (22.3–27.1) 24.8 (22.7–27.3) 25.4 (23.3–29.6) 0.040
Systolic blood pressure (mmHg) 130.0 (120.0–138.0) 130.0 (122.0–140.5) 130.0 (119.0–143.0) 0.130
Diastolic blood pressure (mmHg) 71.0 (63.0–78.0) 73.0 (65.0–80.0) 69.0 (59.0–80.0) 0.200
Fasting plasma glucose (mg/dL) 120.0 (107.0–133.0) 138.0 (119.0–163.5) 184.0 (130.0–213.0) <0.001
Triglycerides (mg/dL) 98.0 (69.0–139.0) 108.0 (76.0–159.0) 131.0 (76.0–184.0) <0.001
Low-density lipoprotein cholesterols (mg/dL) 82.0 (68.0–95.0) 82.0 (68.0–101.0) 82.0 (63.0–106.0) 0.323
Blood creatinine (mg/dL) 1.0 (0.8–1.3) 1.0 (0.8–1.3) 1.0 (0.7–1.4) 0.227
Estimated glomerular filtration rate (mL/min/1.73m2) 70.1 (50.2–84.8) 71.5 (53.0–87.9) 68.1 (45.2–88.7) 0.489
Urine albumin-creatinine ratio (mg/g) 19.2 (8.1–67.1) 28.2 (10.0–119.3) 43.9 (16.8–467.1) <0.001
Treatment <0.001
 Lifestyle modification 43 (11.6%) 36 (8.9%) 8 (9.2%)
 Oral medications only 291 (78.4%) 264 (65.2%) 38 (43.7%)
 Insulin only 10 (2.7%) 24 (5.9%) 7 (8.1%)
 Oral medications + insulin 27 (7.3%) 81 (20.0%) 34 (39.1%)

Table 5.

Characteristics of Participants with and without Dependence by IADL

IADL Independence IADL Dependence p value
Demographic characteristics
Age (years) 70.0 (67.0–75.0) 74.0 (68.0–80.0) <0.001
Gender, n (%) <0.001
 Female 283 (72.0%) 163 (34.7%)
 Male 110 (28.0%) 307 (65.3%)
Educational level, n (%) 0.322
 Illiterate 47 (12.0%) 68 (14.5%)
 Literate 345 (88.0%) 400 (85.5%)
Geriatric characteristics
Polypharmacy 226 (57.5%) 286 (60.9%) 0.354
Mini-mental state examination 27.0 (25.0–29.0) 26.0 (23.0–28.0) <0.001
5-item Geriatric Depression Scale 0 (0–1.0) 0 (0–1.0) 0.120
 Barthel index 100.0 (100.0–100.0) 100.0 (100.0–100.0) <0.001
 Lawton scale 8.0 (8.0–8.0) 6.0 (5.0–7.0) <0.001
Diabetes characteristics
Duration (years) 12.0 (7.0–18.0) 14.0 (8.0–21.0) 0.006
Cardiovascular disease 251 (63.9%) 321 (68.3%) 0.194
 Neuropathy 31 (7.9%) 51 (10.9%) 0.173
 Retinopathy 12 (3.1%) 15 (3.2%) 1.000
Body mass index (kg/m2) 24.6 (22.4–27.1) 25.0 (22.6–27.4) 0.337
Systolic blood pressure (mmHg) 130.0 (122.0–139.0) 130.0 (120.0–140.0) 0.528
Diastolic blood pressure (mmHg) 72.0 (65.0–79.0) 71.0 (62.8–78.0) 0.131
Blood hemoglobin A1c (%) 7.1 (6.5–7.8) 7.1 (6.5–8.0) 0.301
Fasting plasma glucose (mg/dL) 128.0 (114.0–153.5) 131.0 (111.0–152.3) 0.908
Triglycerides (mg/dL) 102.0 (70.0–145.0) 105.0 (76.0–153.0) 0.216
Low-density lipoprotein cholesterols (mg/dL) 83.0 (69.0–99.0) 82.0 (67.0–98.3) 0.357
Blood creatinine (mg/dL) 0.8 (0.7–1.1) 1.1 (0.9–1.4) <0.001
Estimated glomerular filtration rate (mL/min/1.73m2) 76.7 (60.41–92.3) 65.0 (44.8–80.9) <0.001
Urine albumin-creatinine ratio (mg/g) 19.6 (8.7–63.3) 31.6 (10.4–143.4) <0.001
Treatment 0.005
 Lifestyle modification 40 (10.2%) 47 (10.0%)
 Oral medications only 290 (73.8%) 303 (64.5%)
 Insulin only 17 (4.3%) 24 (5.1%)
 Oral medications + insulin 46 (11.7%) 96 (20.4%)

Note: IADL <8.

Abbreviation: IADL, instrumental activities of daily living.

The Association Factors of Cognitive Impairment

Patients with impaired MMSE scores were older, had higher blood Cr, lower eGFR, lower diastolic blood pressure, and greater UACR levels (Table 3). Using univariate regression analysis, it was shown that age, diastolic blood pressure, presence of cerebral vascular disease, disease duration, A1C, FPG, Cr, eGFR, ADL, IADL and GDS-5 were all associated with an increased odds ratio of impaired MMSE. When these variables were further put into multivariate logistic regression analyses, age, presence of cerebral vascular disease, and eGFR were still significantly associated with an increased odds ratio of impaired MMSE (Table 6).

Table 3.

Characteristics of Participants with and without Possible Dementia by MMSE

Normal Possible Dementia p value
Demographic characteristics
Age (years) 71.0 (67.0–76.5) 76.0 (71.0–83.0) <0.001
Gender, n (%) 0.274
 Female 356 (50.8%) 89 (56.0%)
 Male 345 (49.2%) 70 (44.0%)
Educational level, n (%) <0.001
 Illiterate 112 (16.0%) 3 (1.9%)
 Literate 589 (84.0%) 156 (98.1%)
Geriatric characteristics
Polypharmacy 406 (57.9%) 104 (65.4%) 0.100
Mini-mental state examination 28.0 (26.0–29.0) 22.0 (20.0–23.0) <0.001
5-item Geriatric Depression Scale 0 (0–1.0) 0 (0–1.0) 0.003
 Barthel index 100.0 (100.0–100.0) 100.0 (100.0–100.0) <0.001
 Lawton scale 7.0 (6.0–8.0) 6.0 (4.0–8.0) <0.001
Diabetes characteristics
Duration (years) 13.0 (7.0–19.0) 16.0 (9.0–21.0) 0.011
Cardiovascular disease 465 (66.3%) 105 (66.0%) 1.000
 Neuropathy 62 (8.8%) 20 (12.6%) 0.194
 Retinopathy 25 (3.6%) 2 (1.3%) 0.204
Body mass index (kg/m2) 24.8 (22.6–27.3) 24.9 (22.4–27.5) 0.632
Systolic blood pressure (mmHg) 130.0 (122.0–139.0) 129.0 (118.0–145.0) 0.888
Diastolic blood pressure (mmHg) 72.0 (64.0–79.0) 70.0 (60.0–78.0) 0.021
Blood hemoglobin A1c (%) 7.1 (6.5–7.8) 7.2 (6.5–8.1) 0.161
Fasting plasma glucose (mg/dL) 129.0 (113.0–151.0) 134.0 (110.0–167.0) 0.288
Triglycerides (mg/dL) 103.0 (73.0–147.5) 104.0 (74.0–154.0) 0.812
Low-density lipoprotein cholesterols (mg/dL) 82.0 (68.0–98.0) 84.0 (68.0–99.0) 0.500
Blood creatinine (mg/dL) 1.0 (0.8–1.3) 1.1 (0.9–1.5) <0.001
Estimated glomerular filtration rate (mL/min/1.73m2) 71.9 (53.7–87.8) 60.9 (41.6–78.6) <0.001
Urine albumin-creatinine ratio (mg/g) 21.3 (9.0–83.4) 40.4 (13.6–180.7) <0.001
Treatment 0.027
 Lifestyle modification 71 (10.1%) 16 (10.1%)
 Oral medications only 496 (70.8%) 96 (60.4%)
 Insulin only 31 (4.4%) 9 (5.7%)
 Oral medications + insulin 103 (14.7%) 38 (23.9%)

Notes: Literate & mini-mental state examination ≤24/Illiterate & mini-mental state examination ≤13.

Abbreviation: MMSE, Mini-mental State Examination.

Table 6.

Logistic Regression Analysis for Predictors of MMSE, ADL, and IADL Impairment

MMSE Impairment Univariate Multivariate
OR 95% CI p value OR 95% CI p value
Age (years) 1.08 (1.06–1.11) <0.001 1.07 (1.04–1.09) <0.001
Diastolic blood pressure (mmHg) 0.98 (0.97–0.99) 0.009 0.99 (0.98–1.01) 0.310
Cerebral vascular disease 2.42 (1.29–4.54) 0.006 2.43 (1.25–4.74) 0.009
Disease duration (years) 1.03 (1.01–1.05) 0.003 1.01 (0.99–1.03) 0.362
Blood hemoglobin A1c (%) 1.14 (1.01–1.29) 0.034 1.10 (0.94–1.28) 0.226
Fasting plasma glucose (mg/dL) 1.00 (1.00–1.01) 0.024 1.00 (1.00–1.01) 0.257
Blood creatinine (mg/dL) 1.35 (1.07–1.70) 0.011 0.75 (0.45–1.25) 0.272
Estimated glomerular filtration rate (mL/min/1.73m2) 0.98 (0.98–0.99) <0.001 0.99 (0.97–1.00) 0.026
5-item Geriatric Depression Scale 1.35 (1.10–1.66) 0.005
Barthel index 0.95 (0.93–0.98) <0.001
Lawton scale 0.69 (0.62–0.75) <0.001
ADL Impairment Univariate Multivariate
OR 95% CI p value OR 95% CI p value
Age (years) 1.12 (1.08–1.17) <0.001 1.13 (1.08–1.19) <0.001
Male vs Female 0.39 (0.19–0.79) 0.009 0.24 (0.11–0.53) <0.001
Systolic blood pressure (mmHg) 0.98 (0.97–1.00) 0.017 0.98 (0.97–1.00) 0.013
Estimated glomerular filtration rate (mL/min/1.73m2) 0.98 (0.96–0.99) <0.001 0.98 (0.97–1.00) 0.044
Mini-mental state examination 0.79 (0.73–0.84) <0.001
5-item Geriatric Depression Scale 1.79 (1.32–2.42) <0.001
Lawton scale 0.43 (0.36–0.52) <0.001
IADL Impairment Univariate Multivariate
OR 95% CI p value OR 95% CI p value
Age (years) 1.07 (1.05–1.10) <0.001 1.07 (1.04–1.10) <0.001
Male vs Female 4.85 (3.62–6.48) <0.001 4.91 (3.49–6.90) <0.001
Disease duration (years) 1.02 (1.01–1.04) 0.005 1.01 (0.99–1.03) 0.233
Oral medications only vs Diet 0.89 (0.57–1.40) 0.610 1.19 (0.72–1.98) 0.501
Insulin only vs Diet 1.20 (0.57–2.55) 0.632 0.90 (0.38–2.13) 0.812
Oral medications + insulin vs Diet 1.78 (1.03–3.08) 0.040 2.32 (1.24–4.34) 0.009
Blood creatinine (mg/dL) 3.24 (2.31–4.54) <0.001 1.21 (0.73–2.01) 0.458
Estimated glomerular filtration rate (mL/min/1.73m2) 0.98 (0.98–0.99) <0.001 0.99 (0.98–1.00) 0.219
Mini-mental state examination 0.89 (0.86–0.93) <0.001
Barthel index 0.88 (0.81–0.96) 0.003

Abbreviations: MMSE, mini-mental state examination; ADL, activities of daily living; IADL, instrumental activities of daily living.

The Association Factors of Physical Dysfunction

Those patients with an ADL < 100 were also older, had higher blood Cr, lower eGFR, lower systolic blood pressure and greater UACR values (Table 4). Regarding impaired ADL, it was shown that age, gender, systolic blood pressure, eGFR, IADL, GDS-5 and MMSE were all positively associated with an increased odds ratio of abnormal ADL in univariate analysis. After adjustment, we found that age, gender, systolic blood pressure and eGFR remained positively correlated with ADL abnormality (Table 6). Patients with an IADL < 8 were predominantly male, at an older age, had higher blood Cr, lower eGFR and greater UACR values (Table 5). With respect to IADL, it was found that age, gender, presence of nephropathy, disease duration, diabetes treatment, Cr, eGFR, MMSE and ADL were all positively associated with an increased odds ratio of abnormal IADL in univariate analysis. After adjustment, we found that age, gender and diabetic treatment regimens remained positively associated with IADL abnormality (Table 6).

Table 4.

Characteristics of Participants with and without Dependence by ADL

ADL Independence ADL Dependence p value
Demographic characteristics
Age (years) 72.0 (67.0–78.0) 79.5 (73.3–86.0) <0.001
Gender, n (%) 0.011
 Female 417 (50.7%) 29 (72.5%)
 Male 406 (49.3%) 11 (27.5%)
Educational level, n (%) 0.014
 Illiterate 104 (12.7%) 11 (27.5%)
 Literate 716 (87.3%) 29 (72.5%)
Geriatric characteristics
Polypharmacy 484 (58.8%) 28 (70.0%) 0.214
Mini-mental state examination 27.0 (24.0–29.0) 20.5 (17.0–25.0) <0.001
5-item Geriatric Depression Scale 0 (0–1.0) 1.0 (0–1.0) <0.001
 Barthel index 100.0 (100.0–100.0) 80.0 (65.0–90.0) <0.001
 Lawton scale 7.0 (6.0–8.0) 3.0 (2.0–4.8) <0.001
Diabetes characteristics
Duration (years) 13.0 (7.0–19.0) 13.0 (7.0–24.0) 0.679
Cardiovascular disease 547 (66.5%) 25 (62.5%) 0.729
 Neuropathy 75 (9.1%) 7 (17.5%) 0.092
 Retinopathy 27 (3.3%) 0 (0%) 0.631
Body mass index (kg/m2) 24.8 (22.5–27.2) 25.4 (21.9–29.3) 0.336
Systolic blood pressure (mmHg) 130.0 (121.0–140.0) 122.5 (112.3–135.8) 0.019
Diastolic blood pressure (mmHg) 72.0 (64.0–79.0) 74.5 (58.5–78.0) 0.443
Blood hemoglobin A1c (%) 7.1 (6.5–7.9) 7.1 (6.3–8.5) 0.762
Fasting plasma glucose (mg/dL) 130.0 (113.0–153.0) 130.0 (104.3–157.8) 0.755
Triglycerides (mg/dL) 102.0 (73.0–147.0) 140.0 (87.8–182.3) 0.009
Low-density lipoprotein cholesterols (mg/dL) 82.0 (68.0–99.0) 78.0 (66.0–92.8) 0.454
Blood creatinine (mg/dL) 1.0 (0.8–1.3) 1.2 (0.9–1.4) 0.008
Estimated glomerular filtration rate (mL/min/1.73m2) 71.3 (51.5–87.4) 49.4 (39.0–65.1) <0.001
Urine albumin-creatinine ratio (mg/g) 24.5 (9.2–94.9) 40.2 (14.1–108.8) 0.063
Treatment 0.445
 Lifestyle modification 84 (10.2%) 3 (7.5%)
 Oral medications only 567 (68.9%) 26 (65.0%)
 Insulin only 40 (4.9%) 1 (2.5%)
 Oral medications + insulin 132 (16.0%) 10 (25.0%)

Note: ADL <100.

Abbreviation: ADL, activities of daily living.

Discussion

In this study, cognitive and physical assessments conducted in a diabetes clinic revealed that 18.5% of patients had a low MMSE score, and 4.6% and 54.5% had at least one abnormal component in the ADL and IADL instruments, respectively. Moreover, age, renal function, blood pressure, and A1C control status were all associated with an increased risk of impaired MMSE and ADL scores. In line with previous studies, our study findings provide additional evidence surrounding the impact of diabetes on cognition and physical function.1–3 As cognitive and physical dysfunction have both been associated with a poorer ability in self-care and glycemic control for diabetics, additional assessments regarding cognition and physical functions in older persons with diabetes are recommended.13

There are several notable advantages of this study. First, the present study by combining physical and cognitive function assessment service and routine care in older diabetic patients showed these geriatric assessments can be used as one of the components towards more comprehensive care in diabetes. Other fields, such as oncology, nephrology, have previously reported studies on the pivotable role of geriatric assessment for treatment decisions and plans,14,15 while such initiatives were less evaluated in the field of diabetes care. Overall, this study addressed one of the priority issues specified by American Diabetes Association “Comprehensive Medical Evaluation and Assessment of Comorbidities” by developing a feasible geriatric assessment service for older diabetic patients to identify areas of vulnerability that might affect an older individual’s ability to tolerate treatment and lead to rationale interventions to optimize diabetes care.16

Second, our study found that 18.5% of the patients who were evaluated through the MMSE were classified as exhibiting possible dementia, which was higher than the rate of 10% found in a community-based survey of older adults with diabetes.17 We speculate that the higher prevalence seen in this study was possibly due to the fact that cognition screening was conducted in a diabetes outpatient clinic, where patients may be more at risk or may exhibit more comorbid conditions. In fact, a previous survey reported a rate of possible dementia in 24.1% of patients in the outpatient department of a hospital in Taiwan,18 with rates of 12% being reported in the USA and Brazil.2,19 In our study, MMSE scores were negatively associated with glycemic control status according to A1C stratification defined as <7.0%, 7.0–9.0%, and ≥9.0%. This association may be explained by a number of potential mechanisms, including insulin resistance/hyperinsulinemia, as well as the generation of advanced products of glycosylation in the nervous system.20 However, it is also possible that older patients with diabetes and concomitant cognitive dysfunction may be unable to follow complicated medication regimens and therefore their risk of hyperglycemia is increased.21 It is well known that older persons with diabetes are more likely to develop a series of diabetic complications, which could affect the renal, neurological, and cardiovascular systems. Consequently, diabetic complications could cause physical and mental conditions to become even worse, leading to both physical and cognitive disability.22

Third, in this study, we also found that in addition to abnormalities in blood glucose control, renal dysfunction assessed by eGFR and UACR was associated with physical and cognitive impairment in diabetic patients, which is consistent with previous report.22,23 It has been proposed that chronic kidney disease (CKD) in older persons with diabetes may often coexist with risk factors for cognitive impairment, including hyperlipidemia, hypertension, and cardiovascular disease, which in turn can contribute to the development of dementia and physical disability.24,25 Pathophysiologically, CKD may result in vascular endothelial injury or renal insufficiency, both of which have been shown to exacerbate neuronal damage, resulting in alteration amyloid homeostasis.26 In addition, CKD can alter the homeostasis of phosphate calcium and vitamin D, resulting in secondary hyperparathyroidism, which consequently contribute to muscle loss and bone fragility in CKD patients.27 In particular, our study found that older diabetic adults with cognitive and physical function became impaired even if their renal function just mildly decreased (eg, a mean eGFR of around 60 mL/min), which was in line with two previous studies.28,29 It has been suggested that the association of CKD with cognition disorder and functional disability may date back to the early CKD stages. Of note, this study did not show an association between the other diabetic microvascular complications (eg, neuropathy and retinopathy) and cognitive and physical function impairment. Some mechanisms have already been proposed to link microvascular complications to the pathogenesis of cognitive impairment in diabetes, including oxidative stress, inflammation, and others.30 However, although these may be considered common mechanisms for neuropathy, retinopathy and cognitive impairment, there may be other variables that could be of great relevance for the association of neuropathy and retinopathy and physical and cognitive impairment in specific patients.31,32 Further studies are necessary to clarify this issue.

Fourth, in our study patients, 4.6% experienced at least one physical functional problem assessed by ADL with a score less than or equal to 60 seen in 0.8%. Furthermore, 470 (54.5%) patients exhibited at least one abnormal IADL component. This prevalence of functional limitation was similar to that which occurred in a previous study performed in a community of older persons with diabetes.33 It has been proposed that disabilities due to diabetes may be caused by associated complications,34 as well as other prevalent comorbidities in adults with diabetes.35 As shown in our patients, systolic blood pressure and eGFR were positively correlated with ADL abnormality. However, these disabilities in diabetes can be treated and minimized (eg, use of physical therapy for deconditioning and gait training) through early screening of physical function in older persons.

In our study, it was shown that older diabetic adults with cognitive or physical impairment have lower diastolic or systolic blood pressure in comparison with those with normal scores. Hypertension is an important risk factor for vascular disease patients, as it may lead to cognitive impairment due to stroke, and therefore greater disability in the older people.36,37 However, in older people, inappropriate low blood pressure can also increase the risk of dementia, as well as cause physical impairment.38,39 It has been proposed that low blood pressure can cause hypoperfusion in vital organs and tissues, including the brain, heart and musculoskeletal systems, thus resulting in diminished cognitive and physical performance.40,41 Overall, it is suggested that blood pressure management be personalized for the prevention of cognitive and physical function impairment in older persons with diabetes.

In our reports, 8.3% of the patients were diagnosed as having symptoms of depression, which in turn were associated with cognitive and physical abnormality (measured by MMSE and ADL scores). It remains well known that a depressive state is an important factor affecting cognitive dysfunction,42 functional limitations,43 and disease management and the quality of life in older populations with chronic diseases.44,45 In older persons with diabetes, lower cognition or emotional well‐being may decrease their capability to self‐manage their disease; therefore, early detection of cognitive impairment, depressive symptoms, and physical disability in individuals with diabetes is particularly important so that supporting resources can be arranged.

Similar to other studies,35,46 we found that patients with a longer duration of diabetes and older age had lower cognitive and physical function test scores. It has been proposed that mechanisms relating age and diabetes duration to dementia and disability may be mediated by chronic low-level inflammation, which is associated with hyperinsulinaemia and/or insulin resistance, advanced glycation end-products, atherosclerosis and other vascular complications.1,3 In addition, this study also observed that the proportion of participants who used insulin and/or oral glucose-lowering drugs was higher in patients with cognitive and physical function impairment. Because there are no studies showing that glucose-lowering intervention or glucose lowering medications47–49 were efficacious to modulating the risk of cognitive and physical decline, we believe that the correlation was possibly indirect due to a longer duration and severity of the underlying disease.

In order to achieve control goals, diabetes treatment regimens have become more complex, resulting in older persons with diabetes with concomitant disabilities possibly being unable to follow complicated regimens.2,50 Moreover, previous studies have found limitations in ADL, and cognitive impairment could increase the risk of fall, thus resulting in fractures, cerebral trauma, morbidities, mortality, and higher health-care costs.51 Particularly, during the outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and resulting coronavirus disease 2019, physical dysfunction in older persons with diabetes may have been exacerbated due to home confinement causing a reduction in physical activity, an increase in sedentary behavior and unhealthy meal patterns, all of which further bring deleterious effects on diabetes control.52,53 In these circumstances, through assessments of cognition and physical function in older persons with diabetes, individualization and simplification of treatment plans can be implemented. Overall, our study findings may be of value to physicians, as the use of assessment could help to detect decline physical and cognitive functions in older persons with diabetes, in turn prompting earlier intervention.

The study had certain limitations. First, our subjects included those who were capable of visiting our outpatient department, and as a result, they may have had better physical function causing the prevalence of disability to possibly have been underestimated. Second, MMSE scores are influenced by several factors such as age, educational level, and premorbid intelligence of the patient,8 and may therefore not detect mild cognitive impairment. Third, we did not evaluate the personal history of lifestyle habits, such as exercise, smoking habits and alcohol consumption. These factors may have a significant impact on cognitive function. Fourth, our findings were based upon data from a single integrated health system and may not be generalizable for other populations. Besides, multiple comparisons were done in the statistical analysis, which may lead to draw false-positive conclusion.11,12 However, this study was exploratory in characteristics to examine potential risk factors associated with physical and cognitive dysfunction in older diabetic patients, and thus no correction for multiple comparisons was performed.11,12 Nevertheless, additional dedicated studies are needed to confirm the results. Fifth, although we found the relationship between blood pressure and cognitive and physical problems, we did not further analyze classes of antihypertensive medication. According to a recently published meta-analysis, it was reported that there was no evidence that a specific antihypertensive medication class was more effective than others in lowering risk of dementia.54 Lastly, the study employed a cross-sectional design that did not include a control population of older adults without diabetes. Thus, a causal relationship between diabetes-associated factors, and cognitive and physical dysfunction could not be established. Further research remains necessary in order to establish a more definite conclusion.

Conclusion

In summary, this study by designing physical and cognitive function assessment service found that both cognitive and physical function impairment were common in older persons with type 2 diabetes at an outpatient clinic. Age, glycemic control, blood pressure levels and renal function were all associated with cognitive dysfunction and physical limitations. We recommend an integration of cognitive and physical function assessment into clinical practice in older individuals with diabetes, particularly those with risk factors, in order to expedite provision of optimized management plans.

Acknowledgments

The authors are grateful to the Biostatistics Task Force of Taichung Veterans General Hospital for assistance with statistical analysis in this study.

Funding Statement

This work was supported by grants from Taichung Veterans General Hospital, Taiwan (TCVGH-1108201E) and Rong Sing Medical Foundation (RSMF-1090163).

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of Taichung Veterans General Hospital (protocol code CE18117A).

Informed Consent Statement

Patient consent was waived by the Institutional Review Board of Taichung Veterans General Hospital due to the retrospective nature of this study.

Disclosure

The authors report no conflicts of interest in this work.

References

  • 1.Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol. 2018;14(10):591–604. doi: 10.1038/s41574-018-0048-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Munshi M, Grande L, Hayes M, et al. Cognitive dysfunction is associated with poor diabetes control in older adults. Diabetes Care. 2006;29(8):1794–1799. doi: 10.2337/dc06-0506 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Wong E, Backholer K, Gearon E, et al. Diabetes and risk of physical disability in adults: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2013;1(2):106–114. doi: 10.1016/s2213-8587(13)70046-9 [DOI] [PubMed] [Google Scholar]
  • 4.Li CL, Chiu YC, Bai YB, Lin JD, Stanaway F, Chang HY. The co-occurrence of depressive symptoms and cognitive impairment and its relationship with self-care behaviors among community dwelling older adults with diabetes. Diabetes Res Clin Pract. 2017;129:73–78. doi: 10.1016/j.diabres.2017.03.025 [DOI] [PubMed] [Google Scholar]
  • 5.Li CL, Chiu YC, Chang HY, Hsu KH, Bai YB, Wang HH. Association of geriatric conditions and cardiovascular diseases with disability in older adults with diabetes: findings from a nationally representative survey. Geriatr Gerontol Int. 2013;13(3):563–570. doi: 10.1111/j.1447-0594.2012.00935.x [DOI] [PubMed] [Google Scholar]
  • 6.Liu HY, Tsai WC, Chiu MJ, Tang LY, Lee HJ, Shyu YL. Mild cognitive impairment in combination with comorbid diabetes mellitus and hypertension is negatively associated with health-related quality of life among older persons in Taiwan. Qual Life Res. 2019;28(5):1281–1291. doi: 10.1007/s11136-019-02101-3 [DOI] [PubMed] [Google Scholar]
  • 7.Lee IT, Hsu CC, Sheu WH, Su SL, Wu YL, Lin SY. Pay-for-performance for shared care of diabetes in Taiwan. J Formos Med Assoc. 2019;118(Suppl 2):S122–s129. doi: 10.1016/j.jfma.2019.08.011 [DOI] [PubMed] [Google Scholar]
  • 8.Wu JJ, Weng SC, Liang CK, et al. Effects of kidney function, serum albumin and hemoglobin on dementia severity in the oldest old people with newly diagnosed Alzheimer’s disease in a residential aged care facility: a cross-sectional study. BMC Geriatr. 2020;20(1):391. doi: 10.1186/s12877-020-01789-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Chen TB, Yiao SY, Sun Y, et al. Comorbidity and dementia: a nationwide survey in Taiwan. PLoS One. 2017;12(4):e0175475. doi: 10.1371/journal.pone.0175475 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Hoyl MT, Alessi CA, Harker JO, et al. Development and testing of a five-item version of the Geriatric Depression Scale. J Am Geriatr Soc. 1999;47(7):873–878. doi: 10.1111/j.1532-5415.1999.tb03848.x [DOI] [PubMed] [Google Scholar]
  • 11.Althouse AD. Adjust for multiple comparisons? It’s not that simple. Ann Thorac Surg. 2016;101(5):1644–1645. doi: 10.1016/j.athoracsur.2015.11.024 [DOI] [PubMed] [Google Scholar]
  • 12.Bender R, Lange S. Adjusting for multiple testing – when and how? J Clin Epidemiol. 2001;54(4):343–349. doi: 10.1016/s0895-4356(00)00314-0 [DOI] [PubMed] [Google Scholar]
  • 13.Sinclair AJ, Girling AJ, Bayer AJ. Cognitive dysfunction in older subjects with diabetes mellitus: impact on diabetes self-management and use of care services. All Wales Research into Elderly (AWARE) Study. Diabetes Res Clin Pract. 2000;50(3):203–212. doi: 10.1016/s0168-8227(00)00195-9 [DOI] [PubMed] [Google Scholar]
  • 14.Nixon AC, Brown J, Brotherton A, et al. Implementation of a frailty screening programme and Geriatric Assessment Service in a nephrology centre: a quality improvement project. J Nephrol. 2021;34(4):1215–1224. doi: 10.1007/s40620-020-00878-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Presley CJ, Krok-Schoen JL, Wall SA, et al. Implementing a multidisciplinary approach for older adults with cancer: geriatric oncology in practice. BMC Geriatr. 2020;20(1):231. doi: 10.1186/s12877-020-01625-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.American Diabetes Association 4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl1):S40–s52. doi: 10.2337/dc21-S004. [DOI] [PubMed] [Google Scholar]
  • 17.Xiu S, Zheng Z, Liao Q, Chan P. Different risk factors for cognitive impairment among community-dwelling elderly, with impaired fasting glucose or diabetes. Diabetes Metab Syndr Obes. 2019;12:121–130. doi: 10.2147/dmso.S180781 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Tai SY, Huang SW, Hsu CL, Yang CH, Chou MC, Yang YH. Screening dementia in the outpatient department: patients at risk for dementia. ScientificWorldJournal. 2014;2014:138786. doi: 10.1155/2014/138786 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Alencar RC, Cobas RA, Gomes MB. Assessment of cognitive status in patients with type 2 diabetes through the Mini-Mental Status Examination: a cross-sectional study. Diabetol Metab Syndr. 2010;2:10. doi: 10.1186/1758-5996-2-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Karan NS. Assessment of the cognitive status in diabetes mellitus. J Clin Diagn Res. 2012;6(10):1658–1662. doi: 10.7860/jcdr/2012/4837.2649 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Thorpe CT, Gellad WF, Good CB, et al. Tight glycemic control and use of hypoglycemic medications in older veterans with type 2 diabetes and comorbid dementia. Diabetes Care. 2015;38(4):588–595. doi: 10.2337/dc14-0599 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Hong X, Chen X, Chu J, et al. Multiple diabetic complications, as well as impaired physical and mental function, are associated with declining balance function in older persons with diabetes mellitus. Clin Interv Aging. 2017;12:189–195. doi: 10.2147/cia.S123985 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Umegaki H, Iimuro S, Shinozaki T, et al. Risk factors associated with cognitive decline in the elderly with type 2 diabetes: pooled logistic analysis of a 6-year observation in the Japanese Elderly Diabetes Intervention Trial. Geriatr Gerontol Int. 2012;12 Suppl 1:110–116. doi: 10.1111/j.1447-0594.2011.00818.x [DOI] [PubMed] [Google Scholar]
  • 24.Major RW, Oozeerally I, Dawson S, Riddleston H, Gray LJ, Brunskill NJ. Aspirin and cardiovascular primary prevention in non-end stage chronic kidney disease: a meta-analysis. Atherosclerosis. 2016;251:177–182. doi: 10.1016/j.atherosclerosis.2016.06.013 [DOI] [PubMed] [Google Scholar]
  • 25.Jin SH, Park YS, Park YH, Chang HJ, Kim SR. Comparison of gait speed and peripheral nerve function between chronic kidney disease patients with and without diabetes. Ann Rehabil Med. 2017;41(1):72–79. doi: 10.5535/arm.2017.41.1.72 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Bugnicourt JM, Godefroy O, Chillon JM, Choukroun G, Massy ZA. Cognitive disorders and dementia in CKD: the neglected kidney-brain axis. J Am Soc Nephrol. 2013;24(3):353–363. doi: 10.1681/asn.2012050536 [DOI] [PubMed] [Google Scholar]
  • 27.Molina P, Carrero JJ, Bover J, et al. A modulator of musculoskeletal health in chronic kidney disease. J Cachexia Sarcopenia Muscle. 2017;8(5):686–701. doi: 10.1002/jcsm.12218 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Viscogliosi G, De Nicola L, Vanuzzo D, Giampaoli S, Palmieri L, Donfrancesco C. Mild to moderate chronic kidney disease and functional disability in community-dwelling older adults. The Cardiovascular risk profile in Renal patients of the Italian Health Examination Survey (CARHES) study. Arch Gerontol Geriatr. 2019;80:46–52. doi: 10.1016/j.archger.2018.10.001 [DOI] [PubMed] [Google Scholar]
  • 29.Kong JY, Kim JS, Kang MH, Hwang HS, Won CW, Jeong KH. Renal dysfunction is associated with decline of cognitive function in community-dwelling older adults: Korean frailty and aging cohort study. BMC Geriatr. 2020;20(1):462. doi: 10.1186/s12877-020-01862-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Umegaki H, Kawamura T, Umemura T, Kawano N. Factors associated with cognitive decline in older adults with type 2 diabetes mellitus during a 6-year observation. Geriatr Gerontol Int. 2015;15(3):302–310. doi: 10.1111/ggi.12273 [DOI] [PubMed] [Google Scholar]
  • 31.Kawamura T, Umemura T, Hotta N. Curious relationship between cognitive impairment and diabetic retinopathy. J Diabetes Investig. 2015;6(1):21–23. doi: 10.1111/jdi.12234 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Moreira RO, Soldera AL, Cury B, Meireles C, Kupfer R. Is cognitive impairment associated with the presence and severity of peripheral neuropathy in patients with type 2 diabetes mellitus? Diabetol Metab Syndr. 2015;7:51. doi: 10.1186/s13098-015-0045-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Yang YC, Lin MH, Wang CS, et al. Geriatric syndromes and quality of life in older adults with diabetes. Geriatr Gerontol Int. 2019;19(6):518–524. doi: 10.1111/ggi.13654 [DOI] [PubMed] [Google Scholar]
  • 34.Bruce DG, Davis WA, Davis TM. Longitudinal predictors of reduced mobility and physical disability in patients with type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care. 2005;28(10):2441–2447. doi: 10.2337/diacare.28.10.2441 [DOI] [PubMed] [Google Scholar]
  • 35.Kalyani RR, Saudek CD, Brancati FL, Selvin E. Association of diabetes, comorbidities, and A1C with functional disability in older adults: results from the National Health and Nutrition Examination Survey (NHANES), 1999-2006. Diabetes Care. 2010;33(5):1055–1060. doi: 10.2337/dc09-1597 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Stuck AE, Walthert JM, Nikolaus T, Büla CJ, Hohmann C, Beck JC. Risk factors for functional status decline in community-living elderly people: a systematic literature review. Soc Sci Med. 1999;48(4):445–469. doi: 10.1016/s0277-9536(98)00370-0 [DOI] [PubMed] [Google Scholar]
  • 37.Abete P, Della-Morte D, Gargiulo G, et al. Cognitive impairment and cardiovascular diseases in the elderly. A heart-brain continuum hypothesis. Ageing Res Rev. 2014;18:41–52. doi: 10.1016/j.arr.2014.07.003 [DOI] [PubMed] [Google Scholar]
  • 38.Guo Z, Viitanen M, Winblad B. Clinical correlates of low blood pressure in very old people: the importance of cognitive impairment. J Am Geriatr Soc. 1997;45(6):701–705. doi: 10.1111/j.1532-5415.1997.tb01473.x [DOI] [PubMed] [Google Scholar]
  • 39.Paran E, Anson O, Reuveni H. Blood pressure and cognitive functioning among independent elderly. Am J Hypertens. 2003;16(10):818–826. doi: 10.1016/s0895-7061(03)01005-7 [DOI] [PubMed] [Google Scholar]
  • 40.Duschek S, Schandry R. Reduced brain perfusion and cognitive performance due to constitutional hypotension. Clin Auton Res. 2007;17(2):69–76. doi: 10.1007/s10286-006-0379-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Ogliari G, Westendorp RG, Muller M, et al. Blood pressure and 10-year mortality risk in the Milan Geriatrics 75+ cohort study: role of functional and cognitive status. Age Ageing. 2015;44(6):932–937. doi: 10.1093/ageing/afv141 [DOI] [PubMed] [Google Scholar]
  • 42.Richard E, Reitz C, Honig LH, et al. Late-life depression, mild cognitive impairment, and dementia. JAMA Neurol. 2013;70(3):374–382. doi: 10.1001/jamaneurol.2013.603 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Song HJ, Meade K, Akobundu U, Sahyoun NR. Depression as a correlate of functional status of community-dwelling older adults: utilizing a short-version of 5-item Geriatric Depression Scale as a screening tool. J Nutr Health Aging. 2014;18(8):765–770. doi: 10.1007/s12603-014-0542-0 [DOI] [PubMed] [Google Scholar]
  • 44.Jiménez-Cebrián AM, Becerro-de-bengoa-vallejo R, Losa-Iglesias ME, et al. The impact of depression symptoms in patients with Parkinson’s Disease: a novel case-control investigation. Int J Environ Res Public Health. 2021;18(5). doi: 10.3390/ijerph18052369 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Gold SM, Köhler-Forsberg O, Moss-Morris R, et al. Comorbid depression in medical diseases. Nat Rev Dis Primers. 2020;6(1):69. doi: 10.1038/s41572-020-0200-2 [DOI] [PubMed] [Google Scholar]
  • 46.Bruce DG, Davis WA, Casey GP, et al. Predictors of cognitive impairment and dementia in older people with diabetes. Diabetologia. 2008;51(2):241–248. doi: 10.1007/s00125-007-0894-7 [DOI] [PubMed] [Google Scholar]
  • 47.Fink HA, Jutkowitz E, McCarten JR, et al. Pharmacologic interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: a systematic review. Ann Intern Med. 2018;168(1):39–51. doi: 10.7326/m17-1529 [DOI] [PubMed] [Google Scholar]
  • 48.Areosa Sastre A, Vernooij RW, González-Colaço Harmand M, Martínez G. Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev. 2017;6(6):Cd003804. doi: 10.1002/14651858.CD003804.pub2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Yau CK, Eng C, Cenzer IS, Boscardin WJ, Rice-Trumble K, Lee SJ. Glycosylated hemoglobin and functional decline in community-dwelling nursing home-eligible elderly adults with diabetes mellitus. J Am Geriatr Soc. 2012;60(7):1215–1221. doi: 10.1111/j.1532-5415.2012.04041.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Shang Y, Fratiglioni L, Vetrano DL, Dove A, Welmer AK, Xu W. Not only diabetes but also prediabetes leads to functional decline and disability in older adults. Diabetes Care. 2021;44(3):690–698. doi: 10.2337/dc20-2232 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Pijpers E, Ferreira I, de Jongh RT, et al. Older individuals with diabetes have an increased risk of recurrent falls: analysis of potential mediating factors: the Longitudinal Ageing Study Amsterdam. Age Ageing. 2012;41(3):358–365. doi: 10.1093/ageing/afr145 [DOI] [PubMed] [Google Scholar]
  • 52.Marçal IR, Fernandes B, Viana AA, Ciolac EG. The urgent need for recommending physical activity for the management of diabetes during and beyond covid-19 outbreak. Front Endocrinol (Lausanne). 2020;11:584642. doi: 10.3389/fendo.2020.584642 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Trevissón-Redondo B, López-López D, Pérez-Boal E, et al. Use of the Barthel index to assess activities of daily living before and after SARS-COVID 19 infection of Institutionalized Nursing home patients. Int J Environ Res Public Health. 2021;18(14). doi: 10.3390/ijerph18147258 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Ding J, Davis-Plourde KL, Sedaghat S, et al. Antihypertensive medications and risk for incident dementia and Alzheimer’s disease: a meta-analysis of individual participant data from prospective cohort studies. Lancet Neurol. 2020;19(1):61–70. doi: 10.1016/s1474-4422(19)30393-x [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy are provided here courtesy of Dove Press

RESOURCES